PEPTIDE LIGANDS FOR BINDING TO IL-17

    公开(公告)号:US20210122785A1

    公开(公告)日:2021-04-29

    申请号:US17254503

    申请日:2019-06-18

    Abstract: A peptide ligand specific for IL-17 comprising a polypeptide comprising three residues selected from cysteine, L-2,3-diaminopropionic acid (Dap), N-beta-alkyl-L-2,3-diaminopropionic acid (N-AlkDap) and N-beta-haloalkyl-L-2,3-diaminopropionic acid (N-HAlkDap), with the proviso that at least one of said three residues is selected from Dap, N-AlkDap or N-HAlkDap, the said three residues being separated by at least two loop sequences, and a molecular scaffold, the peptide being linked to the scaffold by covalent alkylamino linkages with the Dap or N-AlkDap or N-HAlkDap residues of the polypeptide and by thioether linkages with the cysteine residues of the polypeptide when the said three residues include cysteine, such that two polypeptide loops are formed on the molecular scaffold. Also provided are drug conjugates comprising the peptide ligands conjugated to one or more effector groups and pharmaceutical compositions comprising the conjugates.

    MULTIMERIC BICYCLIC PEPTIDE LIGANDS

    公开(公告)号:US20210101933A1

    公开(公告)日:2021-04-08

    申请号:US17080021

    申请日:2020-10-26

    Abstract: The present invention relates to multimers of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. The invention also describes the multimerization of polypeptides through various chemical linkers and hinges of various lengths and rigidity using different sites of attachments within polypeptides. In particular, the invention describes multimers of peptides which are high affinity binders and activators of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137.

    ANTI-INFECTIVE BICYCLIC PEPTIDE LIGANDS
    19.
    发明公开

    公开(公告)号:US20240083945A1

    公开(公告)日:2024-03-14

    申请号:US18271348

    申请日:2022-01-10

    CPC classification number: C07K7/08 A61K45/06 A61K38/00

    Abstract: The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of the COVID-19 nucleocapsid protein (N-protein). The invention also includes pharmaceutical compositions comprising said polypeptides and to the use of said polypeptides in suppressing or treating a disease or disorder mediated by the COVID-19 nucleocapsid protein (N-protein), such as infection of COVID-19 or for providing prophylaxis to a subject at risk of infection of COVID-19.

Patent Agency Ranking